Adagene Inc.

Adagene Inc.

Biotechnology • Healthcare • Suzhou, China • ADAG (NGM)

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Stock Performance (90 Days)

Data through Dec 23, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

ADAG Group Investment opportunity or not - Relative Strength Index (RSI) & High Return Stock Ideas - bollywoodhelpline.com
bollywoodhelpline.com • Jan 1
Can ADAG stock weather global recession - Weekly Risk Report & Expert Approved Momentum Trade Ideas - moha.gov.vn
moha.gov.vn • Jan 1
Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha
Seeking Alpha • Dec 16
Adagene (Nasdaq: ADAG) earns FDA Fast Track for MSS colorectal cancer combo - Stock Titan
Stock Titan • Dec 16
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - Yahoo Finance
Yahoo Finance • Dec 17

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Adagene Inc. had layoffs?
No layoff events have been recorded for Adagene Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Adagene Inc. have?
Adagene Inc. has approximately 138 employees.
What industry is Adagene Inc. in?
Adagene Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Adagene Inc. a publicly traded company?
Yes, Adagene Inc. is publicly traded under the ticker symbol ADAG on the NGM. The company has a market capitalization of approximately $0.09 billion.
Where is Adagene Inc. headquartered?
Adagene Inc. is headquartered in Suzhou, China.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.